Parameswaran Nair

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

Parameswaran Nair, Márcia Margaret Menezes Pizzichini, Melanie Kjarsgaard et al. · New England Journal of Medicine · 2009 · 1.4K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Klaus F. Rabe, Parameswaran Nair, Guy Brusselle et al. · New England Journal of Medicine · 2018 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

Parameswaran Nair, Sally E. Wenzel, Klaus F. Rabe et al. · New England Journal of Medicine · 2017 · 1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study

Mario Castro, Sameer K. Mathur, Frederick E. Hargreave et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 718 citations

Life Sciences, Immunology, Pharmacotherapy +14